DocumentRX-4384
Issued
Read3 min

NIH to replace disease-based trial funding with five trial-type NOFOs

NIH is replacing institute-specific trial funding notices with five shared NOFOs built around trial type. None had posted as of Nov. 12, with first possible publication in late 2026 or early 2027.

TAG P-2627 · 696 words on the filing

NIH is reorganizing clinical trial funding by trial type instead of disease
NIH is reorganizing clinical trial funding by trial type instead of diseaseDarkoStojanovic / pixabay

Summary of findings

  • NIH is building five cross-institute trial NOFOs: feasibility, early to definitive, multisite, pragmatic and implementation, and network trials.
  • Active NIH NOFOs fell from more than 800 at the start of 2025 to fewer than 500 by year end.
  • As of Nov. 12, none of the new trial-type NOFOs had posted; slides at the May Society for Clinical Trials meeting pointed to late 2026 or early 2027.
  • NHLBI funded 218 investigator-initiated trials through similar NOFOs from fiscal 2017 to 2024; NCCIH adopted a trial-type system in 2017.
  • Trial-type NOFOs will run alongside the existing R01 and R21 parent announcements, which stay open for trial applications.

By Grace Kim

NIH will replace institute-by-institute clinical trial funding notices with five shared notices organized by trial type, and as of Nov. 12 none had posted. NIH announced on Nov. 10 that its institutes are jointly building cross-institute Notices of Funding Opportunity (NOFOs), one set of instructions per trial design rather than per disease.

How does the new funding model work?

The five trial types are feasibility, early to definitive, multisite, pragmatic and implementation, and network trials. A feasibility study of a heart condition, a neurology condition or any other disease would run through the same notice. Historically, many institutes wrote their own trial NOFOs with their own instructions and their own review criteria.

NIH says institutes will now signal priorities through institute, center and office (ICO) profile pages, strategic plans and Highlighted Topics, rather than through the notices themselves. That is how institutes traditionally indicated which diseases and research areas they wanted. Institutes can still issue targeted trial NOFOs when there is a programmatic need, although NIH did not say how it will determine that need exists.

The new notices will sit alongside the parent announcements for clinical trial research project grants (R01) and exploratory/developmental grants (R21). Investigators can keep submitting through those existing broad announcements instead of a trial-type NOFO. NIH says it will roll the new notices out in phases.

The practical effect: applicants retain two established grant routes while five trial-design routes open alongside them.

Why is NIH reorganizing now?

The change follows NIH's consolidation of career development (K) awards, the reclassification of basic experimental studies with humans, and a cut in active NOFOs from more than 800 at the start of 2025 to fewer than 500 by year end. That is a reduction of more than 300 open notices in a single year.

NIH says the trial suite will make it easier for investigators to find the right NOFO, provide consistent instructions for similar trial types, strengthen methodological rigor, make co-funding across institutes easier, and improve internal tracking of trials.

The reorganization is the final step in a year-long contraction of the agency's funding architecture, not a stand-alone exercise.

Does any institute already work this way?

Two do. The National Center for Complementary and Integrative Health moved most of its trials to a trial-type system in 2017. The National Heart, Lung, and Blood Institute funded 218 investigator-initiated trials through a similar set of NOFOs from fiscal 2017 to 2024, an average of about 27 a year.

The trial-type model is established inside NIH rather than imported from outside, which shortens the learning curve for program staff and reviewers.

What could be lost in the switch?

Elizabeth Ginexi, a former NIH program officer, wrote in a Substack post: "When you eliminate targeted NOFOs, you eliminate the funding signal for exactly those areas of science that would otherwise be overlooked." She argues that fewer NOFOs could mean less protection for under-studied areas, early-career investigators and smaller institutions.

Granted AI said: "Early-career researchers without established program-officer relationships, or investigators new to NIH from non-NIH-funded fields, will have a harder time finding the right submission home for their work." The outlet also wrote that the shift is not "necessarily bad" for an application's chances.

No outside groups have publicly backed the changes. The hedge against missing disease signals sits in ICO profile pages, strategic plans and Highlighted Topics, and those documents carry no funding commitment.

Critics worry that disease-specific funding signals will disappear without a substitute that obligates institutes to say what they will fund.

When do applicants see the first notice?

Probably not in 2025. An NHLBI official presented the trial suite in May at the Society for Clinical Trials meeting, where the slides said NIH might publish the new NOFOs in late 2026 or early 2027. As of Nov. 12, none had been posted, and NIH has offered no schedule beyond a phased rollout.

Planners face an open-ended wait with a first possible window in late 2026, and the R01 and R21 parent announcements remain the only dated routes.

via grants.nih.gov (Original)

Share this article:

More from Grace Kim

Grace Kim

Show full bio

Market editor covering companies, deals and strategy in global pharmaceutical industry at PharmInsider.

7 articles

Linked filings

  1. P-6323
  2. K-6477
  3. T-8005
  4. K-4971
  5. P-1559

Next filing »